Ipsen完成收购Memo Therapeutics，获得BK病毒抗体potravitug

Nasdaq rises more than 1% as chip stocks extend rebound from bear market territory
PARIS - Ipsen (Euronext:IPN; ADR:IPSEY) announced today it has completed the acquisition of Memo Therapeutics AG, a late-stage biotech company focused on potravitug, an anti-BK polyomavirus monoclonal antibody.
Potravitug is a monoclonal antibody targeting BK polyomavirus reactivation in kidney transplant recipients. The treatment showed anti-viral response and resolution of BK polyomavirus associated nephropathy in the Phase II SAFE KIDNEY II trial, according to the press release statement.
BK polyomavirus is a common virus that typically remains inactive in the body but can reactivate in people with weakened immune systems, including kidney transplant recipients taking anti-rejection medication. Around 90% of kidney transplant recipients are positive for BK polyomavirus serotype, and high levels of the virus in the blood affect approximately 30% of patients within the first year after transplant.
BK polyomavirus reactivation and associated nephropathy can lead to graft loss and the need for dialysis or re-transplantation. There are currently no approved targeted therapies for BK polyomavirus, and clinical management focuses on balancing graft protection with virus control through reducing immunosuppression.
Over 100,000 kidney transplants are performed worldwide each year. In the United States, more than 28,000 kidney transplants are performed annually, with over 90,000 patients on the waiting list for a transplant.
Ipsen is a global biopharmaceutical company focused on Oncology, Rare Disease and Neuroscience. The company operates in more than 40 countries and brings medicines to patients in more than 100 countries.
The financial terms of the acquisition were not disclosed in the announcement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.